Activity Downloads

To Participate

To participate in this continuing education activity:

1. Review the activity description and objectives.
2. View the activity.
3. Complete the online post-test and activity evaluation.

A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)

 
 View more SIDPEC Activities ►
 

NOTE: If you attended this live CE activity that was held on November 14, 2020 at the SIDP Annual Meeting AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-20-517-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.

Description

These four projects represent some of the exceptional research being conducted by SIDP members. Presentations include the following: Comparing the clinical utility of rapid diagnostics for the treatment of bloodstream infections; Standardized Treatment Algorithm Pathway Improves Mortality in Adults with Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH-Study; In vitro evolution reveals mutations in Candida auris ERG6 as novel a genetic determinant of clinical amphotericin B resistance; Nocardia prophylaxis, treatment, and outcomes of infection in lung transplant recipients: a matched case-control study.

This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.

Learning Objectives

The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:

• Recall the steps to developing a DOOR-MAT for assessment of desirability of antibiotic therapy decisions.
• Determine the impact of a formalized treatment pathway that requires early beta-lactam combination therapy for MRSA bacteremia.
• Describe one mechanism by which Candida auris may become resistant to amphotericin B.
• Identify risk factors for nocardiosis among lung transplant recipients.

Faculty

Sara Alosaimy, PharmD, BCPS
Wayne State University

Kimberly C. Claeys, PharmD, BCPS
University of Maryland School of Pharmacy

Kellie J. Goodlet, PharmD, BCPS, BCIDP
Midwestern University College of Pharmacy

Jeffrey M. Rybak, PharmD, PhD
St. Jude Children’s Research Hospital

Accreditation

Release Date: November 14, 2020
Expiration Date: November 14, 2023

Pharmacists

This activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-517-H01-P has been assigned to this home-study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Sara Alosaimy, Kimberly Claeys and Jeffrey Rybak have no relevant commercial or financial relationships to disclose. Kellie Goodlet is a consultant for Shionogi, AbbVie, and Merck.

Funding

No external support has been received for this activity.

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.